Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 250 results for carcinoma

  1. Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer TSID 12021

    Awaiting development [GID-TA11556] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164)

    This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).

    Clinical guideline
    Last updated
    14 November 2023
    View recommendations

    Sections for CG164

  3. Treatment for lung cancer

    The section of the NICE impact lung cancer report looking at how the disease is treated.

  4. Surgery to the breast:- What is the optimum tumour-free margin width after breast-conserving surgery for women with ductal carcinoma in situ (DCIS) and invasive breast cancer?

    tumour-free margin width after breast-conserving surgery for women with ductal carcinoma in situ (DCIS) and invasive breast cancer? Any...

    Research recommendation
    Published
    11 December 2018

  5. What is the clinical effectiveness of using the VivaScope 1500 and 3000 imaging systems to define margins of lentigo maligna and basal cell carcinoma compared with histological margins determined by Mohs surgery?

    3000 imaging systems to define margins of lentigo maligna and basal cell carcinoma compared with histological margins determined by Mohs...

    Research recommendation
    Published
    12 January 2016

  6. Capecitabine for the treatment of advanced gastric cancer (TA191)

    Evidence-based recommendations on capecitabine for treating advanced gastric cancer in adults.

    Technology appraisal guidance
    Published
    28 July 2010
    View recommendations

    Sections for TA191

  7. Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)

    Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.

    Technology appraisal guidance
    Published
    22 July 2009
    View recommendations

    Sections for TA173

  8. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]

    Awaiting development [GID-TA11538] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Elafibranor for previously treated primary biliary cholangitis (TA1016)

    Evidence-based recommendations on elafibranor (Iqirvo) for previously treated primary biliary cholangitis in adults.

    Technology appraisal guidance
    Published
    14 November 2024
    View recommendations

    Sections for TA1016

  10. Ambulight PDT for the treatment of non-melanoma skin cancer (MTG6)

    Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.

    Medical technologies guidance
    Published
    25 July 2011
    View recommendations

    Sections for MTG6

  11. Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma TS ID 12117

    Awaiting development [GID-TA11653] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer (IPG638)

    Evidence-based recommendations on electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using a small electrical current to improve the effect of chemotherapy given directly into the bladder.

    Interventional procedures guidance
    Published
    30 January 2019
    View recommendations

    Sections for IPG638

  13. What is the impact of using the VivaScope 1500 and 3000 imaging systems in the clinical workflow of melanoma and basal cell carcinoma assessment in secondary care in England, particularly on excision rates, diagnostic accuracy, health related quality of life and associated NHS costs?

    3000 imaging systems in the clinical workflow of melanoma and basal cell carcinoma assessment in secondary care in England, particularly...

    Research recommendation
    Published
    12 January 2016

  14. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor ID 6476

    Awaiting development [GID-TA11584] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)

    Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

    Technology appraisal guidance
    Published
    22 October 2014
    View recommendations

    Sections for TA321